Duchenne muscular dystrophy destroys muscle progressively from early childhood; by adulthood, it's the heart that kills. About 15,000 Americans live with DMD, and nearly all develop cardiomyopathy — yet no FDA-approved therapy treats it. The only candidate is deramiocel, a cell therapy by Capricor Therapeutics given as an IV infusion every three months. On July 29, the FDA's advisory panel voted 9-3 that the cardiac evidence didn't clear the bar. In August, Capricor pivoted: it's now seeking a narrower approval for arm strength instead, and submitted additional data this week in an attempt to push the FDA's deadline past August 22. The FDA's ruling could come any day.

1. The Panel's Case: The Cardiac Data Didn't Clear the Bar (FDA Advisory Committee, 9 votes)

Nine of twelve panelists found the trial's heart-disease evidence too shaky to trust.

The analysis plan kept changing. FDA reviewers found at least three versions of the Statistical Analysis Plan (SAP) produced during the HOPE-3 trial. The agency used SAP v1.1, the earliest prespecified version, under which deramiocel showed no statistically significant difference from placebo on primary or secondary cardiac endpoints at 12 months.

The cardiac benefit didn't reach significance. The Lancet's published LVEF analysis — the heart-function measure the panel focused on — produced a p-value of 0.09 under the updated statistical model — above the 0.05 threshold required for significance. Hypersensitivity reactions hit 42% of deramiocel patients versus 15% on placebo — a visible gap that may have let patients and clinicians guess who got the drug, which makes the trial's functional measures less reliable.

2. But Families Say: The Heart Is What Matters (Parent Project Muscular Dystrophy, Muscular Dystrophy Association)

The pivot toward arm strength leaves DMD's actual killer — cardiomyopathy — still untreated.

Cardiomyopathy doesn't wait for a cleaner trial. Virtually all DMD patients develop the disease, and it's now the leading cause of death in the DMD population — with no approved treatment. Paul Melmeyer, Executive Vice President of Public Policy and Advocacy at the Muscular Dystrophy Association, said of what DMD families testified: "They did an excellent job emphasizing that muscle loss and heart function continue to decline over time, and families cannot get that time back."

Any approval matters, but it isn't enough. Parent Project Muscular Dystrophy said after the pivot announcement that it "appreciates FDA's willingness to accept additional information" but stressed that "time matters." One patient tried to access deramiocel outside the trial under Right to Try — the law that lets terminal patients use unapproved drugs — and was turned down. Patients and families signed a Change.org petition titled "Keep Hope Alive: Approve Deramiocel. Children with DMD are Dying!"

3. Still, the Lancet Validated What They Can Prove (Capricor CEO Linda Marbán; Tricia Flanagan, Azuza Laboratories)

The arm-strength data is Lancet-published and statistically solid — and that's exactly why Capricor is betting on it.

The arm data is real. On July 29 — the same day the FDA panel voted 9-3 against deramiocel — The Lancet published HOPE-3 results showing deramiocel slowed upper limb decline by 54% versus placebo (p=0.03). That's the Lancet's primary finding, and it's statistically significant. The cardiac endpoint is the disputed part; the arm endpoint isn't.

The SAP the FDA relied on was an unsigned draft. CEO Linda Marbán called SAP v1.1 "an unsigned, incomplete internal draft" and said SAP v3.0, finalized before data unblinding, is the correct version. Tricia Flanagan, founder and CEO of Azuza Laboratories and rare disease advocate, argues in the Washington Examiner that companies face "new standards at the end of the approval process instead of predictable ones established from the beginning."

Cell therapy faces a harder road than the drugs already approved. Four antisense oligonucleotide drugs for DMD remain on the market under FDA accelerated approval, even though the FDA hasn't required any of them to confirm clinical benefit. The FDA also published a "plausible mechanism" framework in February 2026 signaling openness to single-trial-plus-confirmatory evidence for rare diseases — a standard critics say the FDA never applied to deramiocel.

Where This Lands

The evidence-standards camp got the 9-3 vote it needed — cardiomyopathy is off the table for now. Families say the pivot means DMD's actual killer still has no treatment. Capricor, with the Lancet's primary finding in hand, is betting the narrower claim gets something across the line. The underlying fight — over what counts as proof when a disease has 15,000 patients and no alternatives — isn't going anywhere regardless of what the FDA decides this week.

Sources